Pharmacists in Byers, CO Accepting Medicare
4 Pharmacists found. Showing 1 - 4
 Dr. Michael Zehnder Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 568 Us Highway 36, Byers, CO 80103 Phone: 303-822-9371 Fax: 303-822-9746 |
 Nimita Vaughn, R.P.H. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 568 Us Highway 36, Byers, CO 80103 Phone: 303-822-9371 Fax: 303-822-9746 |
Lauren Warren Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 568 Us Highway 36, Byers, CO 80103 Phone: 303-822-9371 |
Dr. Izabella Brock, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 568 Us Highway 36, Byers, CO 80103 Phone: 303-822-9371 |
News Archive
Ovarian cancer molecular updates
In a new study a genetic mutation was found in the most common form of ovarian cancer. This according to the US scientists could pave the way for a more effective treatment of the disease. The detailed genetic map already helped scientists identify existing drugs with the potential for treating the mutations found in ovarian cancer tumors and also identified mutations that could respond to new drugs.
New annual campaign to prevent skin cancer
The annual "Euromelanoma Day" campaign is designed to prevent skin cancer among the general public. While there has been considerable interest, it has proved difficult to reach out to some of the at-risk groups. As such, new ways of encouraging these people to go to a dermatologist are being introduced, reveals research from the University of Gothenburg presented at the dermatologist conference in Sweden.
Researcher finds no long-term benefit of using glucosamine for knee joint pain
A popular food supplement used to treat osteoarthritis pain in knee joints has been shown to have no long-term beneficial effect, according to a national study conducted by a University of British Columbia post-doctoral fellow working at the Arthritis Research Centre of Canada
Study reveals low rates of targeted drug use among older black women with early-stage breast cancer
The advent of targeted drugs for a specific type of breast cancer - HER2 positive - has dramatically improved survival rates for women with the disease. But a study led by researchers at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center reveals low rates of use of a targeted drug among older women with early-stage breast cancer of this type, and even lower rates for older black women.
Phase I clinical study of PENNVAX-B preventive DNA vaccine using electroporation technology
Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, and the HIV Vaccine Trials Network (HVTN) announced today the initiation of a phase I clinical study of Inovio's PENNVAX-B preventive DNA vaccine delivered using its proprietary electroporation technology.
› Verified 6 days ago